SB 614 - This act requires the Department of Health and Senior Services, in collaboration with a Missouri university hospital or a hospital or medical center operated by the Department of Veterans Affairs in Missouri, to conduct a study on the efficacy of using alternative medicine and therapies, including, but not limited to, the use of 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine, for the treatment of patients suffering post-traumatic stress disorder, treatment-resistant depression, substance abuse disorders, or who require end-of-life care, as described in the act. Such study shall include a clinical trial of psilocybin, as well as a literature review and the submission of various reports. No person participating in the clinical trial shall be subject to criminal or civil liability or sanction for participating, except in cases of gross negligence or willful misconduct.SARAH HASKINS